Technology | PET-CT | January 21, 2016

Siemens Receives FDA Clearance for Biograph Horizon PET/CT System

Versatile, scalable PET/CT system addresses broad range of indications

Siemens, Biograph Horizon PET CT, FDA clearance

January 21, 2016 — Siemens Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Biograph Horizon positron emission tomography/computed tomography (PET/CT) system, which offers premium performance at a low total cost of ownership. The system leverages proven PET/CT technology to help providers address more clinical indications in oncology, neurology and cardiology, while also introducing new efficiencies and cost savings.

Biograph Horizon enables physicians to visualize small lesions early. The system’s 4 mm LSO crystals scintillate faster and have a higher light output than BGO crystals, resulting in high resolution and better image quality, and enabling Time-of-Flight acquisition. Biograph Horizon’s capabilities are valuable for many indications, like lung cancer – the most common PET/CT indication, at 29 percent of the total exam mix. As more than half of lung cancer patients are diagnosed at a late stage and have an increased likelihood of distant metastasis, more detailed patient data can help clinicians more accurately stage disease and evaluate therapy response, contributing to more effective care pathways.

The recent decision of the U.S. Preventive Services Task Force (USPSTF) to recommend annual lung cancer screening with low-dose CT for high-risk adults has the potential to generate more suspicious findings, for which biopsies are often performed to confirm malignancy. However, 43 percent of these biopsies come back negative, and 1 in 6 result in an adverse event such as lung collapse, which can cost up to 28 times more than the cost of incorporating PET/CT into the evaluation following lung cancer screening. High-contrast, high-resolution PET/CT with Time-of-Flight can help clinicians identify additional diagnostic procedures, like biopsy, that are most appropriate for each lung cancer patient, supporting improved patient outcomes, lower procedure costs and reduced liability risks. To help providers address the growing demand for CT lung exams, Biograph Horizon also can be used as a shared service to support CT overflow, reduce patient wait times and enable scheduling flexibility.

As the smallest PET/CT system with the lowest power requirements, Biograph Horizon minimizes the initial capital investment and is a smart choice for institutions looking to replace their current PET/CT scanner, according to Siemens, as the system will fit into virtually any existing PET/CT exam room. Biograph Horizon offers low operating and maintenance costs to help manage the total cost of ownership, with automated technologies such as gentle system warm-up and automatic standby that extend the system’s economic life in addition to reducing power consumption. And Siemens’ Guardian Program predicts system issues before they occur, lowering costs related to unplanned downtime by 43 percent.

To increase productivity and time spent with patients, Biograph Horizon simplifies staff’s daily routine by automating manual tasks and offering protocol-based exams. For example, the Quanti•QC feature can run quality control procedures overnight, scans can be performed in as fast as 5 minutes, and reconstruction runs alongside acquisition for image delivery just 30 seconds after the scan.

Configured specifically for Biograph Horizon, syngo.via Molecular Imaging Workplace is a cost-effective image processing solution that can expand with providers’ clinical needs. The solution offers automated tools to instantly visualize diagnostic information, measure with confidence and report more comprehensively. syngo.via automates prefetching, preprocessing, and display and comparison of previous findings for up to 45 percent faster processing. Also, ALPHA technology provides automatic registration with organ-based recognition capabilities. EQ•PET normalizes standard uptake value (SUV) measurements across different scanners for more precise calculation of changes in tumor uptake.

For more information: www.usa.siemens.com

Related Content

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topics at the conference. #ASNC #ASNC19 #ASNC2019

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topic at the conference.

Feature | Nuclear Imaging | November 22, 2019 | Dave Fornell, Editor
There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September...
Videos | Nuclear Imaging | November 07, 2019
American Society of Nuclear Cardiology (ASNC) President Rob Beanlands, M.D., shares a couple trends he sees in cardiac...
Videos | Nuclear Imaging | November 06, 2019
Doctor Robert Hendel explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at...
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. The image shows how SPECT allows the reader to distinguish between blood pool activity and radiotracer uptake.

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

Feature | Nuclear Imaging | July 22, 2019 | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS
Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the de
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Videos | Nuclear Imaging | August 21, 2018
Rami Doukky, M.D., professor of medicine, preventive medicine and radiology, and chief of the Division of Cardiology
ASNC Announces Keynote Speakers for 2018 Annual Scientific Session
News | Nuclear Imaging | August 08, 2018
August 8, 2018 — The American Society of Nuclear Cardiology’s (ASNC) Annual Scientific Session, ASNC2018, will kick o
Overlay Init